Pangaea Oncology, S.A. (BME:PANG)

Market Cap	51.36M -14.6%
Revenue (ttm)	14.52M +1.8%
Net Income	-3.60M
EPS	-0.10
Shares Out	35.91M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	102
Open	1.470
Previous Close	1.430
Day's Range	1.430 - 1.470
52-Week Range	1.430 - 1.750
Beta	0.03
Analysts	n/a
Price Target	n/a
Earnings Date	May 12, 2026

About Pangaea Oncology

Pangaea Oncology, S.A., a precision oncology company, provides a range of services to cancer patients in Spain and the rest of European Union countries. The company offers molecular diagnostics, including mutation analysis in tissue and liquid biopsy; gene amplification and translocation testing; immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH); gene expression profiling and transcriptomic signatures; and tumor mutational burden (TMB) and microsatellite instability and (MSI) assessment services. It also provides diagnost...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2006
• Employees: 165
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: PANG

Financial Performance

In 2025, Pangaea Oncology's revenue was 14.52 million, an increase of 1.78% compared to the previous year's 14.27 million. Losses were -3.60 million, 208.3% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 6, 2026

Data Sources Report a data error